Sign in to view content

Subretinal Delivery of RGX-314 for Neovascular AMD: End of Study Phase I/IIa Results

Lejla Vajzovic, MD, FASRS

Video
Published 2021

Related

Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials
Arshad M. Khanani, MD, MA, FASRS
Updates from the Field
2022
Treatment Burden and Vision Analysis of Anti-VEGF Therapies for the Treatment of Neovascular AMD
Rahul Komati, MD
Annual Meeting Talks
2020
Real World Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study
Carl J Danzig, MD
Updates from the Field
2022

Category: AMD - Neovascular

See more